Indian drugmakers anticipate significant benefits from the proposed India-US trade agreement, offering much-needed clarity and stability for the lucrative US pharmaceutical market. This development is expected to boost expansion plans and growth prospects for major companies like Sun Pharma and Dr. Reddy’s, enhancing their competitive edge and strengthening India’s role in global supply chains.